By Fineline Cube 
US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITP) to enhance innovation in the life, health, and medical technology sectors within the Greater Bay Area (GBA). This collaboration aims to leverage the unique strengths of both organizations.
Talent Pool Expansion
The first major project focuses on expanding the biotechnology talent pool. Scheduled to begin in 2027, this long-term initiative will involve HSITP and Pfizer’s Hong Kong unit working together to attract global capability centers to establish and grow their operations in the region. This effort aims to significantly enhance Hong Kong’s biotechnology talent pool.
Clinical Trials and RWE Efficiency
The second project aims to accelerate clinical trials in Hong Kong and cities across the Greater Bay Area. Set to commence in 2026, this initiative will focus on improving the efficiency of real-world evidence (RWE) generation.
Incubation and Acceleration Support
The third key project involves supporting the incubation and acceleration plan of the Hong Kong Shenzhen Innovation and Technology Park. This will provide crucial support for start-ups and innovative enterprises in the region.-Fineline Info & Tech